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Oxidative stress specifically downregulates
survivin to promote breast tumour formation
S Pervin*,1,2,4, L Tran2, R Urman2, M Braga1, M Parveen1, S A Li3, G Chaudhuri2,4,5 and R Singh1,2,4
1Department of Internal Medicine, Charles Drew University of Medicine and Science, Los Angeles, CA 90059, USA; 2Department of
Obstetrics and Gynecology, Los Angeles, CA 90095, USA; 3Hormonal Oncogenesis Laboratory, University of Kansas Cancer
Center, Kansas, KA 66160, USA; 4Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA and 5Department of
Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Background: Breast cancer, a heterogeneous disease has been broadly classified into oestrogen receptor positive (ERþ ) or
oestrogen receptor negative (ER ) tumour types. Each of these tumours is dependent on specific signalling pathways for their
progression. While high levels of survivin, an anti-apoptotic protein, increases aggressive behaviour in ER breast tumours,
oxidative stress (OS) promotes the progression of ERþ breast tumours. Mechanisms and molecular targets by which OS promotes
tumourigenesis remain poorly understood.
Results: DETA-NONOate, a nitric oxide (NO)-donor induces OS in breast cancer cell lines by early re-localisation and
downregulation of cellular survivin. Using in vivo models of HMLEHRAS xenografts and E2-induced breast tumours in ACI rats, we
demonstrate that high OS downregulates survivin during initiation of tumourigenesis. Overexpression of survivin in HMLEHRAS
cells led to a significant delay in tumour initiation and tumour volume in nude mice. This inverse relationship between survivin and
OS was also observed in ERþ human breast tumours. We also demonstrate an upregulation of NADPH oxidase-1 (NOX1) and its
activating protein p67, which are novel markers of OS in E2-induced tumours in ACI rats and as well as in ERþ human breast
tumours.
Conclusion: Our data, therefore, suggest that downregulation of survivin could be an important early event by which OS initiates
breast tumour formation.
Breast cancer is a complex disease that contains many hetero-
geneous cell types (Polyak et al, 2011). Molecular profiling has
categorised five types of breast cancer, each of which contain many
heterogeneous cells that cross-talk with each other and with their
microenvironment through various signalling pathways (Korkaya
et al, 2011; Perou et al, 2011). Despite the heterogeneity in every
aspect of the disease, it is becoming evident that both oestrogen
receptor positive (ERþ ) and ER breast tumours are dependent
on specific signalling pathways that play vital roles in the
progression of these tumours. Survivin, a unique member of
inhibitor of apoptosis (IAP) gene family is selectively over-
expressed in malignant tissues, particularly in aggressive triple-
negative human breast (TNHB) tumours (Muchmore et al, 2000;
Youssef et al, 2008). In addition to inhibiting apoptosis, survivin
increases survival and enhances angiogenesis, all of which
promotes aggressive tumour behaviour and shortened disease-free
survival (Li et al, 2006; Oliveras et al, 2011). Survivin expression in
primary tumours and circulating breast cancer cells provide
valuable information for predicting metastasis and recurrence of
breast cancer (Yie et al, 2006; Adamkov et al, 2010). Since survivin
has a crucial role in drug resistance, it has been essential to
downregulate it to sensitise TNHB tumour cells to various
therapeutic agents (Jha et al, 2012).
While increased survivin expression is a key feature of TNHB
tumours, high oxidative stress (OS) is predominantly a character-
istic of ERþ breast tumours, which comprises 70% of all breast
cancers (Quong et al, 2002; Mobley et al, 2004). Oxidative stress
as assessed by 8-hydroxy deoxyguanosine (DNA damage) or
4-hydroxy-2-nonenal (lipid peroxidation) has been reported to be
high in ERþ human breast tumours (Karihtala et al, 2011).
Mitochondria and NADPH oxidases can induce OS by producing
reactive oxygen species (ROS) such as superoxide, hydrogen
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peroxide and peroxynitrite that increase lipid peroxidation and
DNA damage (Poyton et al, 2009; Coso et al, 2012). NOX1, an
NADPH oxidase, which is known to increase ROS is overexpressed
in 80% of all human breast tumours (Desouki et al, 2005). In
addition, reduced activity of antioxidant enzymes like glutathione
peroxidase (GPX) and superoxide dismutase (SOD) in ERþ breast
tumours are among other mechanisms that increase OS (Tsai et al,
2011; Panis et al, 2012). In ACI rat model of oestrogen-induced
breast tumours, OS has been found to play an important role in
tumour formation, which was attenuated by treatment with anti-
oxidants like vitamin c, butylated hydroxyanisole and a-naphtho-
flavone (Mense et al, 2009; Singh et al, 2012). In epidemiological
studies, dietary anti-oxidants have been found to interact with
endogenous sources of pro- and anti-oxidants to impact breast
cancer risk in women (Sarhar et al, 2008; Li et al, 2009). However,
OS-dependent mechanisms in specific cell types that promote
initiation of tumours remain poorly understood.
We have previously reported that nitric oxide (NO)-induced OS
upregulates an early stress-response gene MKP-1, that promoted
mitochondria-mediated apoptosis in human breast cancer cell lines
(Pervin et al, 2003a). We demonstrate using various in vitro and
in vivo models that high OS suppresses survivin expression. We
also show that high OS increased early re-localisation and decline
of cytosolic survivin that preceded induction of MKP-1 in human
breast cancer cell lines. Furthermore, overexpression of full-length
human survivin in HMLEH-RAS cells reduced tumour volume in
nude mice. Therefore, based on our findings, we conclude that
OS-mediated suppression of survivin in human breast tumours
may be an important event in tumour initiation.
MATERIALS AND METHODS
Materials. Culture media, bovine serum and antibiotics were
purchased from Gibco BRL (Gaithersburg, MD, USA). Human
Insulin solution (#19275) were purchased from Sigma (St Louis,
MO, USA). The following primary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and used at
1:1000 dilutions or otherwise indicated: anti-human survivin (FL-
142, rabbit polyclonal), anti-human MKP-1 (sc-370, rabbit
polyclonal), anti-human b-Actin (SC-81178, mouse monoclonal)
anti-human NOX1 (SC-25545, rabbit polyclonal), anti-human
NOX4 ( SC-21860, goat polyclonal), anti-human pp38MAPK (SC-
7973, mouse monoclonal), anti-human p38 MAPK (SC-7972,
mouse monoclonal), anti-human p67 (SC-7663, goat polyclonal),
anti-human p47 (SC-7660, goat polyclonal) and secondary
peroxidase-conjugated anti-goat antibody (SC-2020). Peroxidase-
conjugated anti-mouse (#7076S) or anti-rabbit (#7074S) secondary
antibodies were purchased from Cell Signaling Technology, Inc.
(Danvers, MA, USA). DETA-NONOate (#82120) was purchased
from Cayman Chemicals (Ann Arbor, MI, USA).
Cell lines. Human breast cancer cell lines MDA-MB-231, MDA-
MB-468 and MCF-7 were obtained from American Type Culture
Collection (Manassas, VA, USA). Human mammary epithelial cells
overexpressing HMLEH-RAS (HRAS) were obtained from Dr
Robert Weinberg (Whitehead Institute at MIT, Cambridge, MA,
USA). These cells were cultured as described before (Pervin et al,
2003b, 2008). For experimental purposes, cells were grown in 5%
FBS, allowed to seed overnight and treated with drugs for various
time periods.
Ethical statements. Tumour samples from TN (ER , PR ,
Her2 ) and ERþ tumour patients were obtained from the
following sources: (a) Cooperative Human Tissue Network
(CHTN) (http://chtn.nci.nih.gov) (tumour samples were collected
using NCI funded resource under OHRP guidelines and waiver of
consent (45CFR46.101b) for anonymised samples; (b) National
Disease Research Interchange (NDRI) (http://ndriresourse.org)
(approved biomedical research and Institutional Review Board
(IRB) protocols from breast tumour patients after obtaining
written consent) and (c) breast tumour and tissue repository at
University of California, Los Angeles (UCLA) (approved biome-
dical research and IRB protocols from consented breast tumour
patients). The research protocol was approved by the Charles Drew
University IRB. This study was carried out in strict accordance
with the recommendation in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) on the Ethics of Animal Experiments of the
Charles Drew University of Medicine and Science. All surgery was
performed under isoflurane anaesthesia, and all efforts were made
to minimise suffering.
Microarray analysis. Total RNA was extracted from control and
16-h DETA-NONOate-treated cells using RNeasy kit (Qiagen,
Valencia, CA, USA), according to the manufacturer’s instructions.
Reverse-transcription and hybridisation was performed essentially
as described previously using Affymetrix U95A v2 chips (Santa
Clara, CA, USA). Data analysis was performed in the Microarray
Suite 5 and Data Mining Tool, v3 (Affymetrix).
Immunohistochemistry. Immunohistochemistry was performed
as described previously (Singh et al, 2009). Briefly, tumour sections
(5–6mm) were deparaffinised in xylene and rehydrated in water.
Antigen retrieval was performed with target retrieval solution for
20–30min. Non-specific staining was blocked with normal serum
and incubated overnight at 4 1C with primary antibodies. This was
followed by reaction with biotinylated anti-rabbit IgG (Vector
Laboratories, Burlingame, CA, USA) for 30min, followed by
treatment with the Avidin:Biotinylated enzyme complex (ABC
complex) (1:100; Vector Laboratories, Burlingame, CA, USA) and
3,30 diaminobenzidine (DAB). In some sets, the sections were
counterstained with haematoxylin. Negative controls omitted the
primary antibodies or replaced them with IgG isotype at the same
concentration. All slides were dehydrated and mounted with
permount. Tissue staining was quantified by quantitative image
analysis (QIA) using the ImagePro 4.01 program (Media Cyber-
netics, Silver Spring, MD, USA) coupled to an Olympus BHS
microscope equipped with a Spot RT colour digital camera
(Diagnostic Instruments Inc., Sterling Heights, MI, USA).
Immunofluorescence. MDA-MB-468 cells were grown in cham-
ber slides, fixed in 4% paraformaldehyde and immunofluorescence
analysis was performed using anti-survivin antibody. Cells were
further incubated with 1:200 dilution of secondary antibody
conjugated with Texas-red and mounted in Prolong anti-fade
solution (Molecular Probes, Eugene, OR, USA) as described
previously (Singh et al, 2006; Braga et al, 2012).
Immunoblot. Immunoblot analysis was performed as described
previously (Pervin et al, 2001, 2008). Briefly, lysates (30 mg) were
resolved electrophoretically on 4–15% gradient SDS–
polyacrylamide gel and electro transferred to a polyvinylidine
difluoride (PVDF) membrane, using a tank blot procedure (Bio-
Rad, Mini Protean II, Hercules, CA, USA). The membranes were
incubated with survivin antibody (1:200), MKP-1 antibody
(1:3000), NOX1 antibody (1:1000) and NOX4 (1:1000) for 2 h at
room temperature followed by subsequent incubation with 1:1000
dilutions of respective secondary antibodies linked to horseradish
peroxidase (GE Healthcare, Piscataway, NJ, USA) for 1 h.
Immunoreactive bands were visualised by the enhanced chemilu-
minescence (ECL) detection system (GE Healthcare).
Semi-quantitative RT–PCR. RT–PCR was performed as
described previously (Pervin et al, 2003a). Total RNA from
DETA-NONOate-treated cells was reverse transcribed, and
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the resulting cDNA was amplified as described previously with the
following primer sets (Life Technologies Inc., Grand Island, NY,
USA): Survivin sense, 50-GCATGGGTGCCCCGACGTTG-30), and
antisense, 50-GCTCCGGCCAGAGGCCTCAA-30; and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) sense, 50-GTGAAGG
TCGGTGTCAACGGATTT-30, and antisense, 50-CACAGTCTTC
TGAGTGGCAGTGAT-30. The identities of the bands obtained
after PCR were confirmed by automated DNA sequencing (data
not shown).
Caspase activity. Caspase activities were measured as described
previously (Pervin et al, 2001; Singh et al, 2002). Control and
treated cells were lysed in insect cell lysis buffer as described in for
30min at 4 1C. The lysates were used for caspase-3 (3mg), and
caspase-9 (6 mg) assays using Ac-DEVD-AMC and Ac-LEHD-
AMC (Pharmingen, San Diego, CA, USA) as caspase-3 and
caspase-9 substrates, respectively. The released AMC after specific
cleavage of respective substrates becomes fluorescent and were
quantified using a fluorometer (Versa FluroTM, Bio-Rad) with
excitation at 380 nm and emission at 440 nm for AMC substrates.
Downregulation of survivin by siRNA treatment. Synthetic
siRNA targeting human survivin (Gene accession #
NM_001012271, Gene ontology, 4694) in MDA-MB-468 cells
and random oligo VIII as a control for nonspecific siRNA effects
were purchased from Dharmacon Research (Lafayette, CO, USA).
Amaxa nucleofecter was used for the transfection (B85%
efficiency) for 24 h following which the cells were treated with
and without DETA-NONOate for another 24 h. We also used
another survivin siRNA (Dharmacon, NM_002759, Gene ontology,
6915) in some of our experiments to confirm the specificity of
survivin siRNA and rule out the possibility of off-target siRNA
effects in our experiments.
Overexpression of survivin. Full-length human survivin cDNA
obtained from Gateway Entry clone (in Gateway vector; Invitrogen,
Grand Island, NY, USA) was amplified by transformation in
presence of 100 mgml 1 Kanamycin. Survivin cDNA entry clone
was transferred into Gateway Destination Vector PUC18 using LR
Clonase system. Amplified clones were transfected into MDA-MB-
468 and HMLE HRAS cells using Transfectamine reagents under
standard conditions (Pervin et al, 2003b).
Analysis of 8-iso-PGF2a levels. Cells after various treatments
were harvested by trysinisation, suspended in PBS (pH 7.4)
containing 0.005% butylated hydroxytoluene and stored at
 80 1C. Total 8-iso-PGF2a levels in the cells were quantified
using a direct 8-iso-PGF2a enzyme immunoassay kit from Assay
Designs (Ann Arbor, MI, USA) according to the supplier’s
instructions. Briefly, hydrolysed samples were incubated with an
8-iso-PGF2a polyclonal antibody for 18 h and the colour was
developed by incubation with p-nitrophenyl phosphate, which was
read at 405 nm.
Measurements of 4-hydroxy-trans-2-nonenal and 4-hydroxy-
alkenals. Oxidative stress was measured by 4-hydroxy-trans-2-
nonenal (4-HNE) using an ELISA kit (Cat# STA-338, Cell Biolabs,
San Diego, CA, USA) as well as 4-hydroxy-alkenals (4-HAE) using
Aldetect Lipid Peroxidation Assay Kit (Enzo Life Sciences, Ann
Arbor, MI, USA) as per manufacturer’s instruction.
Tumour induction in ACI rats by oestrogen treatment. Six- to
eight-week-old female ACI rats (purchased from Harlan Sprague–
Dawley Inc., Indianapolis, IN, USA) were housed individually in an
AAALAC-accredited facility under controlled temperature, humid-
ity, 12 h light–dark cycles, provided with Teklad Rodent Diet 8604
and tap water ad libitum. The animal studies were carried out in
adherence to the guidelines established in the Guide for the Care
and Use of Laboratory Animals (US Department of Health and
Human Resources, NIH, 1985) in the University of Kansas Medical
Center. After a 1-week acclimatisation period, rats were implanted
subcutaneously with E2 pellets (3mg E2 þ 17mg cholesterol),
while rats in the control group were implanted with cholesterol
pellets (17mg cholesterol). At each of the time periods, the animals
were killed using CO2 narcosis and the mammary tumours as well
as normal mammary glands were fixed in formalin or snap frozen
(Li et al, 2004; Weroha et al, 2010).
Xenograft formation. Six- to eight-week-old nude mice were
purchased from Harlan Laboratories Inc., (Placentia, CA, USA)
HMLEH-RAS, MDA-MB-231 or MDA-MB-468 cells (5 106 cells)
suspended in 100 ml matrigel were injected subcutaneously
(10mice per cell line) and tumour growth was monitored. Tumour
volume was calculated as ½ (lengthwidth2) (Sance´au et al, 2002).
Nude mice experiments were performed in accordance with
Institutional Animal Care and Use Committee (IACUC) proce-
dures and guidelines at Charles Drew University.
Cell fractionation. The cell fractionation was done using nuclear
and cytoplasmic extraction reagents from Thermo Scientific,
Rockford, IL, USA. The fractionation was done according to the
manufacturer’s protocol as described previously (Singh et al, 2009).
Statistical analysis. Data are presented as mean±s.d., and
between-group differences were analysed using ANOVA. If the
overall ANOVA revealed significant differences, then pairwise
comparisons between groups were performed by Newman–Keuls
multiple comparison test. All comparisons were two-tailed, and
P-values o0.05 were considered statistically significant. The
experiments were repeated at least three times, and data from
representative experiments are shown.
RESULTS
Redistribution and downregulation of cellular survivin by OS in
breast cancer cells. We have previously reported that OS induced
upregulation of MKP-1 and inactivation of pERK1/2 in MDA-MB-
468 breast cancer cells and promoted apoptosis by Bax integration
into mitochondrial membrane. Nitric oxide-donor DETA-NON-
Oate was used to induce OS in MDA-MB-468 breast cancer cells.
Since induction of MKP-1, an early stress-response gene, occurred
between 3–6 h of exposure to OS (Pervin et al, 2003a), we
performed microarray analysis to examine key early targets of OS
(data not shown). We found that although survivin mRNA
expression was downregulated (83.4±9.5%) at 16 h (Figure 1A);
there was an early (6 h) decline (68.4±12.9%) in cytosolic soluble
survivin protein levels, which was associated with simultaneous
increase in cytoplasmic MKP-1 (3.2±0.5-fold) and membrane-
associated survivin (2.2±0.7-fold) levels (Figure 1B). However,
total survivin protein levels (as assessed by lysing the cells in RIPA
buffer) did not decline until 16–24 h of NO treatment (Figure 1B).
Downregulation of cellular survivin levels was analysed by
immunofluorescence staining (Figure 1C). Cell fractionation
studies show that survivin was located predominantly in the
cytosol in untreated cells (80.4±11.8%) and there was no
significant change after NO treatment (84.8±8.6%) (Figure 1D).
However, when cellular localisation of survivin was examined by
immunofluorescence staining, we noticed brighter aggregates or
clumps of both cytosolic and nuclear survivin as early as 1 h of NO
treatment (data not shown). Since activated pp38 MAPK has been
reported to promote survivin downregulation (Engels et al, 2008),
we also examined the levels of activated p38 MAPK at various time
points of NO treatment. We found increased levels of pp38 MAPK
after 16–24 h of NO treatment, which coincided with decreased
cellular survivin protein and mRNA levels (Figure 1E). Our results
therefore suggest that OS promotes early re-localisation and
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downregulation of cytosolic survivin in MDA-MB-468 breast
cancer cells.
Survivin level in breast cancer cells determines the sensitivity
to OS. Oxidative stress induced by DETA-NONOate (1mM)
treatment was measured by analysis of 8-Iso-PGF2a levels in
MDA-MB-468 cells. We found a significant increase of 8-Iso-
PGF2a levels in DETA-NONOate-treated cells after 16 h
(2.02±0.18-fold) and 24 h (3.3±0.24-fold) (Figure 2A). Oxidative
stress in these cells were further analysed by measurement of lipid
peroxide-mediated complex compounds such as malondialdehyde
(MDA) and 4-hydroxy nonenal (4-HNE) (Figure 2B) as well as
4-hydroxy alkenal (4-HAE) (supplement Figure 1). We found a
significant increase in the levels of MDAþ 4-HNE after 16 h
(1.83±0.18-fold) and 24 h (3.57±0.24-fold) in DETA-NONOate-
treated cells (Figure 2B). Since re-localisation of survivin preceded
the induction of MKP-1, we reasoned that it could be a key event
that may regulate cellular response to OS. To investigate whether
survivin levels determined the sensitivity to OS, the basal levels of
survivin was manipulated in MDA-MB-468 cells. Basal survivin
levels were decreased by transfecting the cells with SMARTpool
survivin small interfering RNAs (siRNA1 and siRNA2) or random
siRNA obtained from Dharmacon. Western blot analysis showed a
75–80% reduction in survivin level with survivin siRNA treatments
when compared with random siRNA (Figure 2C). When these cells
were further exposed to various concentrations of NO (1–2mM
DETA-NONOate), we found that lower concentration of DETA-
NONOate (1mM) was sufficient to significantly reduce survivin
(72±9%) and increase MKP-1 levels (2.4±0.4-fold) after 6 h
(Figure 2E). The increased sensitivity of these cells to NO-induced
OS was further confirmed by analysing caspase-3 and -9 enzyme
activities. Low concentration of NO-treatment was sufficient to
induce both caspase-3 and -9 activities in cells where survivin was
downregulated by siRNA treatment (Figure 2D and F).
Since reduced survivin levels increased sensitivity of breast
cancer cells to OS, we further examined whether overexpression of
survivin would reduce the sensitivity. MDA-MB-468 cells were
transfected with either empty vector or vector containing full-
length human survivin cDNA. The overexpression of survivin was
confirmed by western analysis (Figure 2G). In survivin over-
expressing MDA-MB-468 cells, a higher concentration of NO
(2mM DETA-NONOate) was required to reduce cytosolic survivin
levels, upregulate MKP-1 (Figure 2H) and induce apoptosis
(Figure 2D and F). These results suggest that cellular levels of
survivin may determine the sensitivity of MDA-MB-468 cells to
OS.
We next examined whether survivin levels regulated sensitivity
to OS in other breast cancer cell lines. We utilised established
breast cancer (ZR-75-30, BT474 and MDA-MB-231) and trans-
formed mammary epithelial (HMLEH-RAS) cell lines to examine the
relationship between survivin levels and cell’s sensitivity to OS. The
basal levels of survivin were found to vary within cell lines and
1mM DETA-NONOate was sufficient to significantly downregulate
the low levels of survivin in ZR 75-30 (Figure 3A) and induce
apoptosis (Figure 3B). This amount of OS as produced by 1mM
DETA-NONOate was unable to significantly downregulate higher
levels of survivin or induce apoptosis in all other cell lines studied
(Figure 3B). Higher levels of OS were required for HMLEH-RAS
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Figure 1. OS induces re-localisation and downregulation of survivin in MDA-MB-468 breast cancer cells.MDA-MB-468 cell line was grown to 80%
confluence in six-well plates and treated with DETA-NONOate (1mM) for various time points, after which (A) RNA was extracted and subjected to
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(DETA-NONOate, 2mM) or BT474 (DETA-NONOate, 3mM) to
downregulate survivin (Figure 3C) and induce apoptosis
(Figure 3B). However, even 3–4mM DETA-NONOate was
insufficient to either downregulate survivin or induce apoptosis
in MDA-MB-231 cells (Figure 3A and B). We observed that early
reduction in the cytosolic survivin levels always preceded MKP-1
upregulation (Figure 3C, data for other cell lines not shown).
A higher level of DETA-NONOate was not able to reduce survivin
expression in MDA-MB-231 cells (Figure 3D). Our data, therefore,
suggest that survivin levels determined the sensitivity to OS in
various breast cancer cell lines examined and there was an inverse
relationship between survivin and MKP-1, a sensor of OS.
Survivin expression was suppressed in high OS producing
xenografts from human breast cancer cell lines. Since OS was
found to downregulate survivin levels in human breast cancer cell
lines in vitro, we further examined this relationship in various
in vivo xenograft models in nude mice. It has been shown that Ras
upregulates NOX 1, a NADPH oxidase to increase ROS which
was necessary for Ras-mediated oncogenic transformation
(Mitsushita et al, 2004). We generated transplantable xenografts
by subcutaneous injection of HMLEH-RAS cells in nude mice.
When early (1–7 weeks) and late (10–15 weeks) xenografts from
HMLEH-RAS cells were examined, we found significantly higher
levels of OS as measured by 8-Iso PGF2a levels (1W: 2.1±0.3; 3W:
3.8±0.6; 5W: 6.9±1.6; 7W: 4.2±0.8-fold) in early xenografts
(B0.1–0.3 cm) compared with the larger (B0.8–1.2 cm) xenografts
at later time points (Figure 4A). We also measured MDAþ HNE
(Figure 2B) and MDAþ HAE (supplement Figure 2) in various
stages of H-Ras-induced xenografts. We found a significant
increase in OS in 3 weeks (1.61±0.37-fold) and 5 weeks xenografts
(3.07±0.24-fold) (Figure 4B). Since there was high OS in
xenografts obtained from early stage tumours, we further examined
the expression of various NADPH oxidases (NOX1, NOX2 and
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NOX4) and their regulatory subunits (p67 and p47) that have been
implicated in the production of OS (Mitsushita et al, 2004). There
was high expression of NOX1 and p67 (Figure 4C) in early
xenografts, in addition to p47, another regulatory subunit of
NADPH oxidase (data not shown). Importantly, these early
xenografts with high levels of OS expressed low levels of survivin,
which were highly upregulated in larger xenografts at later time
points. In addition, pERK1/2, which has been implicated in
promoting the progression of breast tumours, was upregulated in
larger xenografts (Figure 4C). The level of cleaved caspase-3 was
higher in early xenografts compared with the larger ones
(Figure 4C). To examine whether downregulation of survivin was
an important event in OS-mediated tumour initiation, we
overexpressed survivin in HMLEH-RAS cells. Survivin overexpres-
sion reduced NOX1 protein expression and reduced tumour
volume when injected in nude mice (Figure 4D–E).
We further examined the xenografts from survivin high (MDA-
MB-231) and low (MDA-MB-468) expressing cell lines. Xenograft
from MDA-MB-231 cell line expressed lower OS as measured by
8-iso-PGE2a levels (Figure 4F) and higher levels of survivin protein
expression (Figure 4F) when compared with xenografts from
MDA-MB-468 cells. Also, OS markers NOX1 and NOX4 as well as
MKP-1 levels were higher in xenografts from MDA-MB-468 when
compared to those from MDA-MB-231 cells (Figure 4G). Our data,
therefore, suggest that high OS suppresses survivin expression in
in vivo xenograft models of breast tumours.
Survivin expression was suppressed while OS was high in E2-
induced mammary tumours in female ACI rats. We further
examined female ACI rats, which are sensitive to oestrogen and
give rise to E2-induced sporadic ductal breast cancers (SDBC) that
remarkably reflects the molecular and histopathology that is
observed in human (Li et al, 2004; Weroha et al, 2010). Oestrogen
treatment of these rats promotes development of atypical ductal
hyperplasia (ADH) at 3m, while at 4.5 and 6 months there is
formation of ductal carcinoma in situ (DCIS) and mammary
tumours in the mammary gland, respectively. High OS has been
reported in E2-induced mammary tumours in ACI rats (Li et al,
2004; Weroha et al, 2010). Using this model, we examined the
levels of OS, which was increased as early as 3 months of E2
treatment (Figure 5A). We analysed the expression levels of NOX1
and its activators p67 and p47 using both immunohistochemistry
(Figure 5B) and western blot analysis (Figure 5C). NOX1, p67 and
p47 were induced as early as 3 months of E2 treatment and
remained upregulated throughout tumour progression (3–6
months). Furthermore, these changes were associated with low
levels of survivin and increased levels of MKP-1 throughout
tumour formation (Figure 5C). Also, there was increased caspase-3
activity (data not shown) and cleaved caspase-3 as detected by
western blot analysis in ADH, DCIS and tumours in this model of
E2-induced tumours (Figure 5C). Our data, therefore, suggest that
high OS suppresses survivin expression in E2-induced breast
tumours in ACI rats.
Reduced survivin expression in human breast tumours with
high levels of NOX1/p67/p47. In various human breast tumours,
particularly those that are ERþ , high amounts of OS has been
found to promote tumour progression. We analysed the levels of
OS-generating enzymes NOX1, and p67 as well as MKP-1 and
survivin levels in ERþ and TN human breast tumours by
immunohistochemistry and western blot analysis. We stained
paraffin-embedded sections from 104 pathologically characterised
human breast tumours of which 63 were ERþ , while 41 were from
TN. Consecutive sections from each patient were stained with
NOX1 (Figure 6A), p67 (Figure 6B) and survivin (Figure 6C). We
found a significant increase in NOX1 (3.6±0.8-fold) (Figure 6A)
and p67 (2.4±0.7-fold) (Figure 6B) in ERþ tumours compared
with the TN tumours. On the other hand, expression of survivin
was found to be significantly decreased (59.4±8.7%) in ERþ
tumours compared with the TN tumours (Figure 6C). We also
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performed western blot analysis using 25 TN (five samples pooled
in each lane) and 20 ERþ (five samples pooled in each lane)
frozen human breast tumours. We found a significant increase in
NOX1 (4.2±0.8-fold), p67 (3.7±0.6-fold) and MKP-1 (2.8±0.6-
fold); while survivin levels was found to be significantly declined by
67.4±9.2% (Figure 6D). Our data, therefore, suggest that OS-
generating proteins are upregulated while survivin levels remain
downregulated in ERþ compared with TN human breast
tumours.
DISCUSSION
Oestrogens have been strongly implicated in the genesis of most
frequently diagnosed SDBC in women (Cavalieri et al, 2002; Geyer
et al, 2012). Since these tumours are more dependent than TN
breast tumours on their microenvironment for development, they
remain difficult to propagate both in vitro and in vivo (Pervin et al,
2010; Mohibi et al, 2011). Although the microenvironment of these
SDBC still remains poorly understood, it has been demonstrated
that OS plays a key role in their initiation and progression
(Shinohara et al, 2010; Toullec et al, 2010). Oxidative stress has
been reported to activate key signal transduction pathways to
increase proliferation of cancer cells in a concentration-dependent
manner (Afanas’ev et al, 2011). In this study, we show for the
first time that OS promotes early and sustained downregulation
of survivin, which could be an important event, particularly
during initiation of some human mammary tumours. This inverse
relationship between high OS and survivin was found in
HMLEH-RAS cell-induced xenografts, in E2-induced mammary
tumours in ACI rats, and also human breast tumours. In
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HMLEH-RAS cell-induced xenografts high OS and low survivin was
found in the initial stages when tumour volume was small.
Whereas during later stages with increased tumour growth, the OS
levels declined. However, in E2-induced tumours in ACI rat model,
high OS persisted throughout tumour formation while survivin
levels remained low.
In addition to mitochondria, NADPH oxidase-dependent ROS
signalling regulates key cellular processes like proliferation,
angiogenesis, cell-cycle arrest and apoptosis in many types of
cancer (Ray et al, 2012). NOX1 is a member of NADPH oxidases
(NOX) family, which are membrane-associated flavoprotein
complexes that have homology to the catalytic subunit of
respiratory burst oxidase (Shinohara et al, 2007). NOX1 expression
is induced by Ras-MEK-MAPK pathway and NOX1-generated
ROS promote angiogenesis among other tumourigenesis related
events (Sumimoto et al, 2008). Our study confirms other findings
that NOX1, which is upregulated in HMLE HRAS cells and produces
OS to promote tumour formation (Mitsushita et al, 2004;
Sumimoto et al, 2008). We also demonstrate that NOX1 was
upregulated in early xenografts, including all stages of E2-induced
SDBC in ACI rats and human breast tumours that are
predominantly ERþ . Members of NOX family form stable
heterodimer with membrane protein p22phox, a docking site for
the SH3 domain-containing regulatory proteins p47 and p67,
which serve as a switch for NOX activation (Shinohara et al, 2007).
We show for the first time that p67 and p47 were highly
upregulated in ERþ human breast tumours when compared with
the ER tumours. Interestingly, in contrast to NOX1, we find TN
breast cancer cell line MDA-MB-468 (Figure 4F) and some TN
human breast tumours express very high levels of NOX4, which is
when downregulated reduced the tumour formation, confirming
the importance of OS during the process (Pervin et al, unpublished
results).
It has been well demonstrated that OS in concentration-
dependent manner regulates aggressive tumour behaviour like
proliferation and angiogenesis in cancer cells (Afanas’ev et al,
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2011). In these reports, low levels of OS promote proliferation by
activating ERK1/2 and Akt pathways while higher levels activate
p38MAPK to induce apoptosis (Kim et al, 2011). Our data,
therefore, support these findings because only in larger xenografts,
a decline in OS increased activated pERK1/2 levels. In all stages of
E2-induced SDBC in ACI rats, increased levels of cleaved caspase-3
and pp38MAPK could be associated with low levels survivin that
persisted throughout tumour formation. However, in the xenograft
model, although there were higher levels of cleaved caspase-3 in
earlier smaller tumours compared with later stages, induction of
apoptosis in certain cell types appears to be a constant feature in
OS-mediated mammary tumours.
It has been shown that survivin levels remain downregulated
when high OS induces apoptosis (White-Gilbertson et al, 2009;
Ahamed et al, 2011). Our findings further provide strong evidences
that OS specifically induce early downregulation of survivin in
human breast cancer cell lines. Unique positioning of survivin in
cancer cells has enabled it to link together multiple functional
molecular networks to promote aggressive behaviour (Kanwar
et al, 2011). There are reports that high survivin promotes
xenograft formation and its downregulation slows tumour growth
(Mesri et al, 2001; Li et al, 2006). These experiments were mostly
performed with aggressive cell lines that probably do not require
OS for tumour initiation.
Due to a tight association between high OS and survivin in our
studies, we have been unable to delineate the significance of one in
the absence of other. Since significant apoptosis occurs in OS-
mediated tumours even when survivin levels were high in
xenograft model, we can only speculate the importance of reduced
survivin in this process. There is high probability that reduced
survivin could promote induction of aneuploidy in certain types of
cells during the initial stages that could increase breast tumour
formation. A direct causal link between oestrogen and induction of
chromosomal instability and aneuploidy has been reported in
oestrogen-associated neoplasms (Li et al, 2003).
Since OS plays an important role in E2-induced tumours, we
conclude that downregulation of survivin could be an important
early step in their initiation and progression by promoting
induction of aneuploidy.
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